Moreover, SLF2‐deficient lymphoma cells did not show any sensitization to a ubiquitin E1 inhibitor (Appendix Fig S11C) further underscoring the specificity of the synthetic lethality to SUMOi. The gene discussed is SLF2; the disease is lymphoma.